Gene Therapy for Inherited Deafness Shows Safety and Promise, Study Finds

A peer-reviewed journal has reported that the inner ear’s naturally protected environment — where the body’s immune system is less active than elsewhere — allows doctors to deliver gene therapy to one ear and then the other without triggering a harmful immune response. The findings, published in Nature Medicine, add to a growing body of evidence that this approach could offer a curative treatment for a specific type of congenital deafness (deafness that a person is born with due to a genetic fault).

The journal described the inner ear as “immune-privileged” — a term used in medicine to describe areas of the body where immune reactions are naturally suppressed, reducing the risk that the body will attack a treatment before it can work. That quality appears to make sequential treatment of both ears possible, which matters because most people with this condition experience hearing loss in both ears.

Gene therapy works by delivering a corrected copy of a faulty gene into the body’s cells. In this context, it targets the specific genetic fault responsible for this form of inherited deafness rather than managing symptoms.

The research does not apply to all types of deafness — only to the particular inherited form under study. Readers with concerns about their own hearing, or a child’s, should speak to their GP in the first instance. NHS 111 can also advise on accessing audiology or specialist services.